An efficacy trial of the malaria vaccine SPf66 in Gambian infants--second year of follow-up

Vaccine. 1998 Jan;16(1):62-7. doi: 10.1016/s0264-410x(97)00159-x.

Abstract

In 1994, 630 Gambian infants were immunized with three doses of the synthetic polypeptide malaria vaccine SPf66 or with a control vaccine. No significant protection against first or total attacks of malaria was observed among the children who received SPf66. However, the period of follow-up was short. Thus, 532 children were followed for a second malaria transmission season during which 291 episodes of malaria were detected. Protective efficacies of SPf66 against first attacks of malaria and against all attacks of malaria were 8% [95% CI-20%, 30%] and 2% [95% CI-26% 24%] respectively. SPf66 did not provide any significant degree of protection to Gambian infants during a second year of follow-up.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Female
  • Follow-Up Studies
  • Gambia
  • Humans
  • Infant
  • Malaria Vaccines / therapeutic use*
  • Malaria, Falciparum / prevention & control*
  • Male
  • Plasmodium falciparum*
  • Protozoan Proteins*
  • Recombinant Proteins*
  • Vaccines, Synthetic / therapeutic use

Substances

  • Malaria Vaccines
  • Protozoan Proteins
  • Recombinant Proteins
  • SPf66 protein, Plasmodium
  • Vaccines, Synthetic